There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > KIR2DL3


Brief Information

Name:Killer cell immunoglobulin-like receptor 2DL3
Target Synonym:P58.2 MHC Class-I Specific NK Receptor,MHC Class I NK Cell Receptor,CD158b2 Antigen,KIR-K7b,KIR-K7c,KIR2DS5,CD158b,KIR2DL,NKAT2A,NKAT2B,GL183,NKAT,P58,Receptors, KIR2DL3,Cl-6,Killer Cell Immunoglobulin-Like Receptor Two Domains Long Cytoplasmic Tail 3,Nat
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
KI3-H5257 Human Human KIR2DL3 / CD158b2 Protein, Fc Tag

Synonym Name



Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is also known as CD158 antigen-like family member B2, KIR-023GB, Killer inhibitory receptor cl 2-3, MHC class I NK cell receptor, NKAT2a, NKAT2b, Natural killer-associated transcript 2, p58 natural killer cell receptor clone CL-6, p58.2 MHC class-I-specific NK receptor, CD158b2 and KIR2DL3, which is a single-pass type I membrane protein and belongs to the immunoglobulin superfamily.KIR2DL3 is a receptor on natural killer (NK) cells for HLA-C alleles (HLA-Cw1, HLA-Cw3 and HLA-Cw7). KIR2DL3 can inhibit the activity of NK cells thus preventing cell lysis.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lirilumab IPH-21; NN-1975; IPH-2101; IPH-2102; BMS-986015 Phase 2 Clinical Novo Nordisk A/S Solid tumours; Head and Neck Neoplasms; Neoplasms; Hodgkin Disease; Smoldering Multiple Myeloma; Myelodysplastic Syndromes; Multiple Myeloma; Urinary Bladder Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details

This web search service is supported by Google Inc.